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Abstract
Background: Poor adherence to lithium is very common in bipolar patients and it is a frequent
cause of recurrence during prophylactic treatment. Several reports suggest that attitudes of bipolar
patients interfere with adherence to lithium. The Lithium Attitudes Questionnaire (LAQ) is a brief
questionnaire developed as a means of identifying and grouping the problems patients commonly
have with taking lithium regularly. The original version is validated in patients, but a validated
version in Portuguese is not yet available.
Methods: One-hundred six patients with bipolar disorder (DSM-IV criteria) criteria under lithium
treatment for at least one month were assessed using LAQ. LAQ is a brief questionnaire
administered under interview conditions, which includes 19 items rating attitudes towards
prophylactic lithium treatment. We analysed the internal consistency, concurrent validity,
sensitivity and specificity of the Portuguese version of LAQ.
Results: The internal consistency, evaluated by Cronbach's alpha was 0.78. The mean total LAQ
score was 4.1. Concurrent validity was confirmed by a negative correlation between plasma lithium
concentration and total LAQ score (r = -0,198; p = 0.048). We analysed the scale's discriminative
capacity revealing a sensitivity of 69% and a specificity of 71% in the identification of negative
attitudes of bipolar patients.
Conclusion: The psychometric assessment of the Portuguese version of LAQ showed good
internal consistency, sensitivity and specificity. The results were similar to the original version in
relation to attitudes of bipolar patients towards lithium therapy.
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Bipolar disorder (BD) is a chronic, recurrent illness, affect-
ing 0.3% to 1.5% of the population. BD is associated with
important social and economic costs, including loss of
productivity, lower quality of life, incremented healthcare
costs and suicide [1,2]. Lithium remains as the mainstay
in bipolar disorder treatment. It reduces manic symptoms
in 73% of the treated patients, twice as many as placebo,
and prevents the recurrence of mood episodes [3-6].
Non-adherence rates to long-term prophylactic pharma-
cotherapy range from 20 to 66% [6-9]. The median dura-
tion of lithium adherence is around 76 days [10]. Poor
adherence to lithium is, unfortunately, very common and
it is the most frequent cause of recurrence during prophy-
lactic treatment [10-14]. Several studies reported that neg-
atives attitudes, such as non-acceptance of lithium
effectiveness, opposition to the treatment, denial of the
disease and fear of side effects interfere with adherence
[15-17].
The 'Lithium Attitudes Questionnaire' (LAQ) was devel-
oped as means of identifying and grouping the problems
that patients commonly have when taking lithium regu-
larly. The 'LAQ' evaluates the main advantages and disad-
vantages of lithium treatment. Its subscores are then used
to describe patients who expressed opposition to continu-
ing on lithium, and those who missed their hypomanic
episodes. The original English version is validated in psy-
chiatric population and has shown adequate reliability
[18].
The purpose of the present study was to validate the Por-
tuguese version of LAQ and to describe its psychometric
properties. This validation may help the assessment of
attitudes that may affect adherence in bipolar patients
from Brazil and Portugal.
Methods
2.1. Subjects
The study was conducted in two psychiatric outpatient
services specialized in mood disorders in the city of Porto
Alegre, Brazil. The psychiatric outpatients selected were
diagnosed with bipolar disorder according to DSM-IV cri-
teria.
Patients were evaluated for both their symptoms and gen-
eral state in weekly consultations. Patients participated in
psycho-educational groups about the use of lithium and
support groups to discuss topics related to the disorder.
After giving the informed consent, patients were inter-
viewed and had a lithium blood level assessment sched-
uled.
The study was approved by the Ethics Committee of the
Hospital Materno Infantil Presidente Vargas and Hospital
de Clínicas de Porto Alegre, where the research took place




Every subject gave information about marital status, work,
age, gender and level of education.
Current clinical status
Bipolar patients were diagnosed using a Structured Clini-
cal Interview (SCID) and all patients were followed up
prospectively using mood charts. The clinical status was
also assessed on the day of the LAQ application and blood
collection for lithium measurements.
LAQ
LAQ is a brief questionnaire comprising 19 items which
rate attitudes towards prophylactic lithium treatment.
Seven subscales assess the resistance to prophylaxis in
general (LAQ 1), denial of therapeutic effectiveness of
lithium as a prophylactic agent (LAQ 2), fear of side
effects (LAQ 3), difficulties with the daily routine medica-
tion intake (LAQ 4), denial of the severity of the illness
(LAQ 5), negative attitudes toward drugs in general (LAQ
6) and lack of information about lithium prophylaxis
(LAQ 7) [16,18]. The correct answers are: 1-N; 2-Y; 3-N; 4-
N; 5-Y; 6-N; 7-Y; 8-N; 9-Y; 10-N; 11-Y; 12-N; 13-Y; 14-N;
15-Y; 16-N; 17-Y; 18-Y; 19-N. The items are posed using a
Yes/No format with low scores indicating positive atti-
tudes and high scores indicating negative attitudes The
total LAQ score is obtained by adding together the
responses to the 19 points. If a patient obtains a score > 4
this indicates a negative attitude versus lithium treatment,
as shown in Table 1.
The adaptation of LAQ was carried out using an instru-
ment translated into Portuguese after translation/back
translation procedures [19,20]. The items resulting in
optimal word equivalence with the original text were ana-
lysed and discussed by five psychiatric investigators who
agreed with the final version. After these procedures,
investigators who were fluent in both English and Portu-
guese evaluated the degree of equivalence between the
original English and the Portuguese version. Finally, the
comprehension of each item was assessed with a sample
of 106 bipolar patients. The Portuguese version of the
LAQ used in this study was found to be appropriate and
correctly understood by psychiatric patients.
The LAQ was administered on one occasion and the time
spent in the application of LAQ was 6–8 minutes. On this
occasion venous blood was drawn from each patient toPage 2 of 7
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on the morning of the interview.
We analysed the internal consistency, concurrent validity
in relation to plasma lithium concentration, sensitivity
and specificity. The psychometric characteristics of the
LAQ are derived from the administration of the question-
naire, including all the subjects who completed the anal-
ysis. Internal consistency was assessed by Cronbach's
Alpha for the total scale and each individual item. Con-
current validity was studied considering plasma lithium
concentration and the score obtained using LAQ. Pearson
coefficient was used for verify correlation between LAQ
scores and plasma lithium concentration. The cutt-off
used was 4 (from the original reference).
To study the sensitivity, specificity and positive and nega-
tive predicative of the LAQ, we have used the proportion
of adherent bipolar patients as compared to plasma lith-
ium concentration. A discriminate analysis was carried
out using data obtained by means of LAQ application.
Lithium plasma concentration
The subjects were instructed to be at the hospital early in
the morning, without having taken their lithium dose,
respecting a 12-hour interval between the last dose of lith-
ium and the blood sampling. Venous blood was collected
from each patient into Vacutainer tube containing edetic
acid. The whole blood was then centrifuged 1600 × g for
10 minutes and the plasma removed by aspiration. A 1/20
dilution in water was made of 99 μl of plasma. Lithium
concentrations were measured in plasma dilutions by the
indirect method, using an Instrumentation Laboratory
CELM Flame Photometer. Assays were performed in
duplicate [21].
Statistical analysis
Statistical analysis was performed using SPSS for Win-
dows – Version 12.0 (SPSS Inc., Chicago, IL, USa). The
Kolmogorov-Smirnov test was used to compare the
observed cumulative distribution to a theoretical cumula-
tive distribution function. ANOVA test was used for com-
pare LAQ scores and plasma levels of lithium. Pearson's
correlation coefficient was performed to examine the rela-
tionship between plasma lithium concentration and LAQ
scores. The binomial variables (clinical state and LAQ
scores) were compared using Chi-Square test.
Results
The sample included 73 (68.9%) women, with a mean
age 43.5 ± 9.8 and 33 men with a mean age of 41.6 ± 9.7.
At the time when the present study was carried out, there
were 77 (71.7%) euthymic patients, 12 (11.1%) manic
and 17 (17,2%) depressed, according to the mood charts
and physician is assessment. 40 (37.7%) of patients were
smokers, 70 (66%) used coffee on a regular basis, and 68
(64.2%) used tea on a regular basis.
The answers to the LAQ were obtained from 106 bipolar
patients and the mean score on the LAQ TOTAL was 4.1 ±
0.5 for men and 4.1 ± 0.4 for women. Therefore, gender
did not seem to influence any of the adherence parame-
ters evaluated using LAQ scale or lithium plasma. The
Table 1: Questionário de Atitudes em relação ao Lítio (LAQ)
Marque com um X as respostas que o Sr considerar correta.
1. O Sr(a). acha perfeitamente aceitável tomar LÍTIO por vários anos? (1)S (2) N
2. O Sr(a). toma LÍTIO somente quando sente necessidade? (1)S (2) N
3. O Sr(a) acha que vale a pena tomar LÍTIO, apesar dos efeitos colaterais? (1)S (2) N
4. Tomar LÍTIO conforme receitado pelo seu médico é fácil no seu dia-dia? (1)S (2) N
5. É melhor aliviar o estresse, do que tomar LÍTIO para ficar bem (estável)? (1)S (2) N
6. Sr(a). considera que a LÍTIO é uma necessidade atual para o seu bem-estar? (1)S (2) N
7. Sr(a) se preocupa com os efeitos colaterais do LÍTIO mesmo quando sente-se bem? (1)S (2) N
8. A maioria das pessoas que o Sr(a) conhece acham necessário que tome o LÍTIO? (1)S (2) N
9. Sr(a). ás vezes tenta esquecer que está doente, e por isso para de tomar os seus comprimidos de LÍTIO? (1)S (2) N
10. Sr(a). confia tanto nos seus comprimidos de LÍTIO, que se por algum motivo fosse interrompido o seu tratamento, o Sr(a) 
ficaria preocupado?
(1)S (2) N
11. As pessoas precisam lhe lembrar de tomar o LÍTIO? (1)S (2) N
12. Sr(a). aceita bem o LÍTIO, mesmo sabendo que é necessário fazer exames de sangue e check up regulares? (1)S (2) N
13. Sr(a). ás vezes pensa que o LÍTIO é uma maneira artificial de lhe manter bem, e que deveria conseguir viver sem ela? (1)S (2) N
14. É fácil lembrar as horas certas de tomar LÍTIO? (1)S (2) N
15. Sr(a). freqüentemente duvida que a sua condição de saúde seja tão seria, que justifique o uso do lítio por vários anos? (1)S (2) N
16. Sr(a). tem um conhecimento adequado sobre os efeitos da LÍTIO? (1)S (2) N
17. Se o Sr(a) ficasse bem por vários meses, deixaria de tomar a LÍTIO? (1)S (2) N
18. Se a sua rotina diária mudar por alguma razão, o Sr(a). terá dificuldade de tomar seus comprimidos de LÍTIO? (1)S (2) N
19. Sr(a). está convencido dos efeitos benéficos do LÍTIO baseado na sua própria experiência? (1)S (2) NPage 3 of 7
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Table 2.
All LAQ items were answered by patients in every test ses-
sion. No patient posed objections to completing the ques-
tionnaire. The internal consistency coefficient was
obtained for the 19 items as shown Table 3 and the mean
Cronbach's alpha of 0.78 for the total scale indicates that
the items are sufficiently homogeneous.
We analysed the scale's discriminative capacity for bipolar
patients by means of the performance of 'attitudes toward
lithium treatment' on sensitivity and specificity analysis.
The calculated sensitivity and specificity were 69% and
71%, respectively.
Concurrent validity was assessed using plasma lithium
concentration and showed a significant negative correla-
tion between the total LAQ score and lithium levels (r = -
0.198; p = 0.048). The number of patients scoring posi-
tively for each LAQ subscore during the test completion is
shown in Figure 1.
Figure 1 shows that LAQ's subscore 3, regarding the side
effects of lithium, was considered a disadvantage of treat-
ment by the majority of respondents. Patients also
reported subscore 5 (denial of illness severity) as a source
of noncompliance with Li prophylaxis. Subcultural atti-
tudes, as assessed using subscore 6, was considered as a
disadvantage in 44.4% of the positive respondents and
dissatisfaction with factual knowledge of Li (subscore 7)
was rated as a disadvantage in 42,5% of the positive
respondents.
We observed statistically significant differences between
the LAQ 1 and scores of patients currently manic or
euthymic and significant differences between the LAQ 2
and scores of patients currently manic, depressed or
euthymic (Pearson Chi-Square < .05) (see Table 4). This
result indicates that acute symptoms interfered in lithium
treatment adherence.
Discussion
Unfortunately, poor adherence to lithium is very com-
mon and previous studies have already pointed out that it
is the most frequent cause of recurrence during prophylac-
tic lithium treatment [13,14,22]. Therefore, it is reasona-
ble try and identify potential reasons which lead patients
to discontinue lithium treatment. The Portuguese version
of the LAQ scale may become particularly useful because
Portuguese is a language which is spoken by a population
of 202 million people, including Brazil and Portugal.
Hence, it is reassuring to find that the psychometric assess-
ment of the Portuguese version of LAQ showed good sen-
sitivity and specificity. In a sample of bipolar patients the
Portuguese version of the LAQ used the cut-off point of 4,
which mirrors the English original version; this indicates
that four or more points at LAQ reflect the existence of
negative attitudes towards lithium treatment.
The LAQ scale showed very good internal consistency and
all items presented a Cronbach's alpha above 0.7, as inter-
nationally accepted. In the convergent validity analysis we
observed a negative correlation between lithium plasma
levels and total scores of LAQ. This was due to the fact
that, in non-adherent patients (plasma lithium levels <
0.6 mmol L or > 1.2 mmol L), negative attitudes about
lithium treatment were greater than those observed
among adherent patients.
The analysis of each LAQ subscores showed that subscore
3, regarding side effects of lithium, was considered an
important disadvantage of treatment by the majority of
respondents, which is in line with the original study. This
result is important because fear of side effects, and not the
side effects themselves seem to pose important barriers for
the use of lithium. Indeed, Scott and Pope [15] reported
that many patients with affective disorders feared harmful
effects of the use of lithium in the long run. Patients also
reported that denial of the severity of the illness, negative
attitudes toward drugs in general and lack of information
about lithium prophylaxis were also identified as caveats
of lithium therapy. These results are in accordance with
previous studies which highlighted the fact that non-
adherent bipolar patients tend to present negative atti-
tudes towards lithium treatment [14-17,23].
Further, the scale proved to be sensitive to mood changes,
as differential scores were captured during depression,
mania and euthymia. Euthymic patients showed more
positive attitudes than manic and depressed patients. The
scores obtained in items such as LAQ 1 (resistance to
prophylaxis in general) and LAQ 2 (denial of therapeutic
effectiveness of lithium as a prophylactic agent) were the
Table 2: Demographics and Scores for lithium treatment 
parameters in 106 bipolar patients
Average SD
Age 42,9 9,79
Education level 9,2 3,4
Plasma lithium 0,86 0,25
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who were either manic or depressed. These results were
reported in the original English version, where
hypomanic patients showed more resistance to prophy-
laxis in general [24]. Negative attitudes strengthen the
Percent of adherent (adh) and nonadherent (noadh) patients scoring positively for each LAQ subscoreFigure 1
Percent of adherent (adh) and nonadherent (noadh) patients scoring positively for each LAQ subscore. (1) resistance to proph-
ylaxis in general; (2) denial of therapeutic effectiveness of lithium as a prophylactic agent; (3) fear of side effects (LAQ 3); (4) dif-
ficulties with the daily routine medication intake; (5) denial of the severity of the illness; (6) negative attitudes toward drugs in 

















Table 3: Internal Consistency Reliability
Scale Mean Scale Variance Corrected item Alpha
Question 1 3,7453 9,4107 0,5778 0,7543
Question 2 4,0283 10,904 0,2149 0,7803
Question 3 4 10,2667 0,5044 0,7654
Question 4 4,0094 10,4666 0,42 0,7703
Question 5 3,9717 10,4659 0,3496 0,7732
Question 6 4,066 10,9385 0,2968 0,7779
Question 7 3,6415 10,5179 0,1792 0,7882
Question 8 3,8679 10,8014 0,1311 0,7886
Question 9 3,8585 10,1417 0,3713 0,7715
Question 10 3,8386 9,6788 0,5355 0,7588
Question 11 3,9245 10,0704 0,4628 0,7654
Question 12 3,9811 10,3806 0,4058 0,7701
Question 13 3,6887 9,6069 0,4884 0,7619
Question 14 3,9434 10,1491 0,4538 0,7664
Question 15 3,7547 10,0726 0,3451 0,774
Question 16 3,6792 10,9247 0,547 0,7979
Question 17 3,8868 10,0442 0,4325 0,7671
Question 18 3,9717 10,7135 0,2343 0,7798
Question 19 4,0094 10,3523 0,4828 0,7671
The internal consistency coefficient (Cronbach's alpha) obtained was 0.78 for the total scale and was superior to 0.7 for each of the 24 items, 
indicating sufficiently homogeneous.Page 5 of 7
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role in the effectiveness of lithium long-term prophylaxis.
Several studies [22,24] found a possible effect of educa-
tion in improving adherence. It is reasonable to suppose
that this effect is in some extent mediated via patient's
aquisition of a positive attitude towards lithium treatment
[16]. LAQ is a rapid, reliable screening instrument which
presents a good level of acceptability by patients. The sub-
categories of items, from which the LAQ subscores derive,
describe specific problem areas, most of which are consid-
ered by patients to represent noteworthy disadvantages of
lithium therapy [18]. The importance of this finding is
that all factors can be assessed routinely in day-to-day
clinical practice, with no need of long questionnaires. The
identification of negative attitudes toward lithium treat-
ment may be an important tool in order to increase adher-
ence and consequently reduce the number of relapses,
economic burden and rates of mortality associated with
BD.
It is important to highlight the fact that individuals who
are non-adherent to lithium are also likely to fail to agree
to participate or fail to adhere with research protocols.
Another point to be considered is that we did not assess
current symptom severity and comorbidities. It is also
important to mention that this was a crossover study, as
we assessed attitudes about the use of medication in only
one occasion. As yet, there is no research on the stability
or variability of such beliefs over time.
Conclusion
In conclusion, the LAQ scale is a rapid and reliable screen-
ing instrument which may help to identify negative atti-
tudes towards lithium treatment. The present study
showed that the Portuguese version is valid for the assess-
ment of bipolar patients in Portuguese-speaking coun-
tries.
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